Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia
Open Access
- 25 April 2024
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-10
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy is effective in the treatment of relapsed/refractory acute B-lymphoblastic leukemia (R/R B-ALL); however, patients who receive CAR-T therapy are predisposed to infections, with considerable detrimental effects on long-term survival rates and the quality of life of patients. This study retrospectively analyzed infectious complications in 79 pediatric patients with R/R B-ALL treated with CAR-T cells at our institution. Overall, 53 patients developed 88 infections. Nine patients experienced nine infections during lymphodepletion chemotherapy, 35 experienced 41 infections during the early phase (days 0–+ 30 after infusion), and 29 experienced 38 infections during the late phase (day + 31–+ 90 after infusion). Pathogens were identified in 31 infections, including 23 bacteria, seven viruses, and one fungus. Four patients were admitted to the intensive care unit for infection and one died. In a univariate analysis, there were ten factors associated with infection, including tumor load, lymphodepleting chemotherapy, neutrophil deficiency and lymphocyte reduction, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), etc. In a multivariate analysis, CRS ≥ grade 3 was identified as a risk factor for infection (hazard ratio = 2.41, 95% confidence interval: 1.08–5.36, P = 0.031). Therefore, actively reducing the CRS grade may decrease the risk of infection and improve the long-term quality of life of these patients.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (Nos. 81770193)
- Medical Research Project of Jiangsu Provincial Health and Family Planning Commission (ZD2021006)
- Jiangsu Project (No. BE2021654)
- Suzhou Key Laboratory of Childhood Leukemia (SZS201615)
This publication has 41 references indexed in Scilit:
- Current status and perspectives of regulatory T cell-based therapyJournal of Genetics and Genomics, 2022
- Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)Annals of Oncology, 2022
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trialThe Lancet Oncology, 2022
- Regulatory T cell therapy: Current and future design perspectivesCellular Immunology, 2020
- Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paperInfection, 2020
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- CAR T‐Cell Therapy in Hematologic Malignancies: A Voyage in ProgressClinical Pharmacology & Therapeutics, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and managementBlood Reviews, 2019
- Hypogammaglobulinemia due to CAR T‐cell therapyPediatric Blood & Cancer, 2017